Verona Pharma (VRNA) has disclosed a new risk, in the Litigation & Legal Liabilities category.
Verona Pharma faces significant business risks tied to its obligations under the Medicaid Drug Rebate Program and other governmental pricing programs. Non-compliance with these programs could lead to substantial penalties, including reimbursement demands, fines, or termination from vital federal programs, which would restrict federal payments for their drugs. Changes in legislation, such as the American Rescue Plan Act of 2021, which removes the cap on rebate liabilities, further complicate compliance and could adversely affect Verona Pharma’s financial stability and growth. The company must meticulously manage its reporting and pricing strategies to mitigate the potential material adverse effects on its business operations.
Overall, Wall Street has a Strong Buy consensus rating on VRNA stock based on 7 Buys.
To learn more about Verona Pharma’s risk factors, click here.
